Research letterTofacitinib for the treatment of alopecia areata in preadolescent children
References (5)
- et al.
Tofacitinib for the treatment of alopecia areata and variants in adolescents
J Am Acad Dermatol
(2017) Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
J Am Acad Dermatol
(2017)
Cited by (47)
Clinical response to oral tofacitinib in pediatric patients with alopecia areata
2023, JAAD Case ReportsCitation Excerpt :Studies investigating its use for pediatric AA are scarce. Craiglow et al reported positive outcomes with 5 mg oral tofacitinib twice a day for pediatric AA.10 Our patient population was equally distributed with respect to sex but substantially varied in terms of AA onset (as early as the age of 4 years, latest onset at the age of 14 years), disease subtype (5/10 patchy AA, 1/10 AT, 1/10 ophiasis, 3/10 AU) and severity (SALT scores ranging from 40% to 100%), and eyebrow (6/10) and eyelash involvement (7/10).
Treatment of pediatric alopecia areata: A systematic review
2022, Journal of the American Academy of DermatologyCitation Excerpt :Clinical trials are currently evaluating the efficacy of tofacitinib to treat AA in adults.99 Six case series and reports evaluated systemic tofacitinib for the treatment of AA in 28 pediatric patients.95-100 Of these patients, 82% showed complete or partial response and all nonresponders were patients with AU.
Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
2022, Journal of the American Academy of DermatologyAlopecia Areata: New Treatment Options Including Janus Kinase Inhibitors
2021, Dermatologic ClinicsCitation Excerpt :This was supported by another study that treated eight adolescents aged 12 to 19 with tofacitinib (5 mg twice a day) for a range of 5 to 18 months, yielding greater than 50% regrowth in scalp hair in all patients by 5 months.24 As for pediatric patients, Craiglow and King25 reported success treating four pediatric patients 8 to 10 years old with oral tofacitinib (5 mg twice a day) for a range of 6 to 15 months, with three of the four patients showing significant regrowth, and two of which showed complete regrowth by 6 months. In addition, baricitinib, a JAK 1 and 2 inhibitor, is another drug that has been used to treat AA.
Treatment Options for Alopecia Areata in Children and Adolescents
2024, Pediatric DrugsTofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review
2024, Skin Research and Technology
Funding sources: Dr King received support from the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.
Disclosure: Dr Craiglow has served on advisory boards, received honoraria from, and is a consultant to Pfizer. Dr King has served on advisory boards for Pfizer and Aclaris Therapeutics and is a consultant to Pfizer, Concert Pharmaceuticals, and Eli Lilly and Company.